A Review of the Response to Oral Antidiabetes Agents in Patients with Type 2 Diabetes

References

• . American Diabetes Association. Standards of medical care in diabetes—2009. Diabetes Care. 2009;32( suppl 1):S13–S61
   PubMed Web of Science ®Google Scholar
• . Nathan DM, Buse JB, Davidson MB, . Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29(8):1963–1972
   PubMed Web of Science ®Google Scholar
• . Rodbard HW, Blonde L, Braithwaite SS, ; American Association of Clinical Endocrinologists Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13 ( suppl 1):1–68
   PubMedGoogle Scholar
• . Hawkins D, Bradberry JC, Cziraky MJ, Talbert RL, Bartels DW, Cerveny JD. National Pharmacy Cardiovascular Council treatment guidelines for the management of type 2 diabetes mellitus: toward better patient outcomes and new roles for pharmacists. Pharmacotherapy. 2002;22(4):436–444
   PubMed Web of Science ®Google Scholar
• . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study Group. Lancet. 1998;352(9131):837–853
   PubMed Web of Science ®Google Scholar
• . Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care. 2008;31(1):81–86
   PubMed Web of Science ®Google Scholar
• . Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005–2012
   PubMed Web of Science ®Google Scholar
• . Canadian Agency for Drugs and Technology in Health. Briefing paper: Minimal clinically important difference in HbA1c. Canadian Agency for Drugs and Technology in Health; 2008
   Google Scholar
• . US Food and Drug Administration. Pargluva™ Muraglitazar (BMS-298585). Advisory Committee Briefing Document. Rockville MD: US Food and Drug Administration; 2005. http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4169B2_01_01-BMS-Pargluva.pdf. Accessed April 12, 2010
   Google Scholar
• . Cook MN, Girman CJ, Stein PP, Alexander CM. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care. Diabet Med. 2007;24(4):350–358
   PubMed Web of Science ®Google Scholar
• . Charpentier G, Vaur L, Halimi S, . Predictors of response to glimepiride in patients with type 2 diabetes mellitus. Diabetes Metab. 2001;27(5 pt 1):563–571
   PubMed Web of Science ®Google Scholar
• . Wolffenbuttel BH, Sels JP, Rondas-Colbers GJ, Menheere PP. Prognostic factors for successful insulin therapy in subjects with type 2 diabetes. Neth J Med. 1999;54(2):63–69
   PubMed Web of Science ®Google Scholar
• . Buse J, Hart K, Minasi L. The PROTECT Study: final results of a large multicenter postmarketing study in patients with type 2 diabetes. Precose Resolution of Optimal Titration to Enhance Current Therapies. Clin Ther. 1998;20(2):257–269
   PubMed Web of Science ®Google Scholar
• . Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care. 2006;29(9):2137–2139
   PubMed Web of Science ®Google Scholar
• . U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995;44(11):1249–1258
   PubMed Web of Science ®Google Scholar
• . Topp BG, Waters SB, Alexander CM. Differences in reported efficacy between oral anti-hyperglycemic agents largely reflect differences in baseline A1C. Paper presented at: 68th Annual American Diabetes Association Scientific Sessions; San Francisco, CA; 2008
   Google Scholar
• . Chapell R, Teutsch S, Gould AL, Bloomgarden ZT. Meta-analytic regression demonstrates equivalent efficacy of sitagliptin, pioglitazone and rosiglitazone: influence of baseline HbA1c. Abstract 512-P. Abstract presented at: 68th Annual American Diabetes Association Scientific Sessions; San Francisco, CA; 2008
   Google Scholar
• . Tajiri Y, Takei R, Mimura K, Umeda F. Indicators for the efficacy of pioglitazone before and during treatment in Japanese patients with type 2 diabetes. Diabetes Technol Ther. 2007;9(5):429–437
   PubMed Web of Science ®Google Scholar
• . Blüher M, Lübben G, Paschke R. Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. Diabetes Care. 2003;26(3):825–831
   PubMed Web of Science ®Google Scholar
• . Kim YM, Cha BS, Kim DJ, . Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus. Diabetes Res Clin Pract. 2005;67(1):43–52
   PubMed Web of Science ®Google Scholar
• . Nichols GA, Alexander CM, Girman CJ, Kamal-Bahl SJ, Brown JB. Treatment escalation and rise in HbA1c following successful initial metformin therapy. Diabetes Care. 2006;29(3):504–509
   PubMed Web of Science ®Google Scholar
• . Gavin LA, Barth J, Arnold D, Shaw R. Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control. Endocr Pract. 2000;6(4):305–310
   PubMedGoogle Scholar
• . Fujioka K, Seaton TB, Rowe E, . Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2000;2(3):175–187
   PubMed Web of Science ®Google Scholar
• . Igarashi M, Jimbu Y, Kimura M, Hirata A, Yamaguchi H, Tominaga M. Effect of pioglitazone on atherogenic outcomes in type 2 diabetic patients: a comparison of responders and non-responders. Diabetes Res Clin Pract. 2007;77(3):389–398
   PubMed Web of Science ®Google Scholar
• . Hirose T, Miyashita Y, Takagi M, Sumitani S, Kouhara H, Kasayama S. Characteristics of type 2 diabetic patients responding to voglibose administration as an adjunct to sulfonylurea. Diabetes Res Clin Pract. 2001;54(1):9–15
   PubMed Web of Science ®Google Scholar
• . Tomioka S, Ogata H, Tamura Y, . Clinical characteristics influencing the effectiveness of metformin on Japanese type 2 diabetes receiving sulfonylureas. Endocr J. 2007;54(2):247–253
   PubMed Web of Science ®Google Scholar
• . Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229–234
   PubMed Web of Science ®Google Scholar
• . Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16(2):434–444
   PubMed Web of Science ®Google Scholar
• . Stratton IM, Adler AI, Neil HA, . Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412
   PubMed Web of Science ®Google Scholar
• . Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287(3):360–372
   PubMed Web of Science ®Google Scholar
• . Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 2003;26(6):1902–1912
   PubMed Web of Science ®Google Scholar
• . Baksi A, James RE, Zhou B, Nolan JJ. Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea. Acta Diabetol. 2004;41(2):63–69
   PubMed Web of Science ®Google Scholar
• . Kerenyi Z, Samer H, James R, Yan Y, Stewart M. Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2004;63(3):213–223
   PubMed Web of Science ®Google Scholar
• . Weissman P, Goldstein BJ, Rosenstock J, . Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. Curr Med Res Opin. 2005;21(12):2029–2035
   PubMed Web of Science ®Google Scholar
• . Nathan DM, Buse JB, Davidson MB, . Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2008;31(1):173–175
   PubMed Web of Science ®Google Scholar
• . Herman WH, Dirani RG, Horblyuk R, . Reduction in use of healthcare services with combination sulfonylurea and rosiglitazone: findings from the Rosiglitazone Early vs SULfonylurea Titration (RESULT) study. Am J Manag Care. 2005;11(4):273–278
   PubMed Web of Science ®Google Scholar
• . Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med. 2008;168(18):1975–1983
   PubMedGoogle Scholar
• . Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care. 2008;31(8):1479–1484
   PubMed Web of Science ®Google Scholar
• . Goldfine AB, Fonseca VA, Jones MR, Wang AC, Ford DM, Truitt KE. Long-term safety and tolerability of colesevelam HCl in subjects with type 2 diabetes. Horm Metab Res. 2010;42(1):23–30
   PubMed Web of Science ®Google Scholar
• . Staels B. A review of bile acid sequestrants: potential mechanism(s) for glucose-lowering effects in type 2 diabetes mellitus. Postgrad Med. 2009;121(3 suppl 1):25–30
   PubMed Web of Science ®Google Scholar
• . Goldfine AB. Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: targeting the bile acid pathway. Curr Opin Cardiol. 2008;23(5):502–511
   PubMed Web of Science ®Google Scholar
• . Mitro N, Mak PA, Vargas L, . The nuclear receptor LXR is a glucose sensor. Nature. 2007;445(7124):219–223
   PubMed Web of Science ®Google Scholar
• . Suzuki T, Oba K, Igari Y, . Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7–36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. J Nippon Med Sch. 2007;74(5):338–343
   PubMedGoogle Scholar
• . Nathan DM, Buse JB, Davidson MB, ; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203
   PubMed Web of Science ®Google Scholar
• . Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care. 2000;23(11):1605–1611
   PubMed Web of Science ®Google Scholar
• . Black C, Donnelly P, McIntyre L, Royle PL, Shepherd JP, Thomas S. Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007(2):CD004654
   Google Scholar
• . Levy P. The current unmet need in type 2 diabetes mellitus: addressing glycemia and cardiovascular disease. Postgrad Med. 2009;121 (3 suppl 1):7–12
   PubMed Web of Science ®Google Scholar
• . Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A; Rosiglitazone Clinical Trials Study Group.Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care. 2001;24(2):308–315
   PubMed Web of Science ®Google Scholar
• . Reasner CA. Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors. J Cardiovasc Pharmacol. 2008;52(2):136–144
   PubMed Web of Science ®Google Scholar
• . Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group.Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290(4): 486–494
   PubMed Web of Science ®Google Scholar
• . Glucophage (metformin hydrochloride) tablets, Glucophage XR (metformin hydrochloride) extended-release tablets [package insert]. New York, NY: Bristol-Myers Squibb Company. Updated January 2009
   Google Scholar
• . Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970;19( suppl):789–830
   PubMed Web of Science ®Google Scholar
• . Halimi S, Le Berre MA, Grangé V. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study. Diabetes Res Clin Pract. 2000;50(1):49–56
   PubMed Web of Science ®Google Scholar
• . Phillips P, Karrasch J, Scott R, Wilson D, Moses R. Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin. Diabetes Care. 2003;26(2):269–273
   PubMed Web of Science ®Google Scholar
• . Feinböck C, Luger A, Klingler A, ; Austrian Glimepiride Study Group. Prospective multicentre trial comparing the efficacy of, and compliance with, glimepiride or acarbose treatment in patients with type 2 diabetes not controlled with diet alone. Diabetes Nutr Metab. 2003;16(4):214–221
   PubMedGoogle Scholar
• . Satoh N, Ogawa Y, Usui T, . Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care. 2003;26(9):2493–2499
   PubMed Web of Science ®Google Scholar
• . Munscher C, Potthoff F, Lubben G, . Pioglitazone and insulin for treatment of patients with type-2-diabetes mellitus—A medical and pharmacoeconomic analysis [in German]. Diabetes und Stoffwechsel. 2004;13(3):121–130
   Google Scholar
• . Wang G, Wang X, Zhang Q, Ma Z. Response to pioglitazone treatment is associated with the lipoprotein lipase S447X variant in subjects with type 2 diabetes mellitus. Int J Clin Pract. 2007;61(4):552–557
   PubMed Web of Science ®Google Scholar
• . Umpierrez G, Issa M, Vlajnic A. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Curr Med Res Opin. 2006;22(4):751–759
   PubMed Web of Science ®Google Scholar
• . Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab. 2008;10(1):82–90
   PubMed Web of Science ®Google Scholar